Physicians' Academy for Cardiovascular Education

GLP-1 RA & CVD

Follow news, literature and expert opinions on GLP-1 as emerging target in the management of T2DM & Cardiovascular Disease

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD

Two choices of drugs that reduce CV risk in T2DM

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD

Translating GLP-1RA trial outcomes to cardiology practice: Which patients will benefit?

10' education - Dec. 10, 2018 - Prof. Lars Rydén, MD - Stockholm Sweden

GLP-1 receptor agonists: The cardiovascular benefits beyond glucose control

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Filip K. Knop - Copenhagen, Denmark

Diabetes & CVD: Time for a multifactorial approach

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - John E Deanfield, MD - London, United Kingdom

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany

Comprehensive overview of antidiabetic drug classes: mechanisms, benefits and risks

10' education - Mar. 29, 2018 - Prof Cliff Bailey - Birmingham, UK

Current management of heart failure and T2DM

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Martin Cowie - London, UK

Guidance from outcome trials: What are the clinical implications?

10' education - May 28, 2018 - ESC HF 2018 - Vienna, Austria - Prof. Faiez Zannad - Nancy, France
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (3/3)

Practical management of cardiovascular risk: Lessons from latest diabetes trials

10' education - June 25, 2018 - Prof. Lars Rydén - Stockholm, Sweden - Online CME
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice

Diabetes: How to reduce risk from a cardiovascular perspective?

10' education - June 25, 2018 - Prof. Diederick Grobbee - Utrecht, The Netherlands

Translation of novel approaches in CVD & diabetes to clinical practice

10' education - Mar. 22, 2018 - John Deanfield, Francesco Cosentino, Filip Knop
Preventing Cardiovascular Disease in Patients with T2DM - How to apply novel outcome data with GLP-1 RA to clinical practice (1/3)

The cardiovascular challenge for primary care in diabetes

10' education - June 14, 2018 - Prof. Richard Hobbs - Oxford, UK - Online CME

Clinical trials in diabetes and CVD: What did we learn?

10' education - Mar. 22, 2018 - Filippo Crea, Angelyn Bethel, Eduard Montanya

What are the key mechanisms of CV benefit of novel diabetes drugs?

10' education - May 1, 2018 - Lina Badimon, Jochen Seufert, Naveed Sattar

What is the science driving CVD and T2DM?

10' education - Mar. 22, 2018 - Wouter Jukema, Stephan Jacob, Ulf Landmesser

Hypoglycemia in cardiovascular medicine: why worry?

10' education - Mar. 7, 2018 - Prof Guntram Schernthaner - Vienna, Austria - Online CME

Key classes of antidiabetic drugs – How do they work?

10' education - Feb. 14, 2018 - Prof Cliff Bailey - Birmingham, UK - Online CME

Diabetes cardiovascular outcome trials

10' education - Feb. 14, 2018 - Prof. Lawrence Leiter, MD - Toronto, ON, Canada - Online CME

Diabetic patients with chronic kidney disease may benefit more from GLP-1 analogue treatment

10' education - Nov. 15, 2017

Natural history of DM: Focus on micro- and macrovascular complications

10' education - Feb. 13, 2018 - Prof. Kausik Ray, Imperial College London, UK - Online CME

Diabetes therapies and CVD – Does the ‘how’ matter more than the how much?

10' education - Oct. 27, 2017 - Boston, MA, USA - Dr. Stephen Wiviott - Brigham & Women's Hospital, Boston, USA

New therapeutic options can make a difference for diabetic patients with high CV risk

3' education - Aug. 29, 2017 - Prof. John E Deanfield, MD - London, UK

Cardiovascular protection in type 2 diabetes

5' education - Aug. 29, 2017 - Prof. Lars Rydén, cardiologist, Stockholm, Sweden

Brief update on the LEADER cardiovascular outcomes trial

10' education - Oct. 15, 2017 - Prof. Neil Poulter, cardiologist, London, UK

Targeting CVD in diabetes: Novel strategies to tackle the risk

10' education - Apr. 11, 2019 - EuroPrevent 2019 - John Deanfield, MD
Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

EuroPrevent 2019 Prof. Deanfield reflects on a new era in CVD prevention for patients with diabetes. He discusses how can we prevent diabetes and manage diabetes exposure in the general population.

The cardiovascular challenge for primary care in diabetes

10' education - Apr. 11, 2019 - EuroPrevent 2019 - Prof. Richard Hobbs, MD
Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

EuroPrevent 2019 Prof. Hobbs emphasizes the relevance of targeting CVD prevention in diabetic patients and discusses how we can modify CVD risk factors in these patients.

Diabetes, Cardiology & Novel Therapeutic Approaches: Science, Outcomes and Practice

CME accredited E-Learning

Online-CME - This course consists of 3 lectures
This course consists of 3 lectures

CME accredited course focussed on novel diabetes treatment approaches in the prevention of CVD in patients with T2DM. Member registration (free) is needed to enroll in this course

Treatment with GLP-1RA results in reduction of MACE in type 2 diabetes patients with established CVD

Literature - Feb. 12, 2019 - Hernandez AF et al. - The Lancet 2018

Albiglutide was superior to placebo with respect to MACE in T2DM patients in the Harmony Outcomes trial without differences in serious adverse events.

Two choices of drugs that reduce CV risk in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Feb. 7, 2019 - Prof. John Deanfield, MD
Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Cardio Diabetes Masterclass Dubai Prof. John Deanfield discusses two new drug classes that benefit T2DM patients in terms of CV risk, with different modes of action indicating different potential for clinical implications.

Translating outcomes to practice: Focus on GLP-1 RA, which patients will benefit?

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Neil Poulter MD - London, UK
Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

Prof. Neil Poulter discusses lessons that can be drawn from recent CVOTs on treatment and prevention strategies in patients with CV risk and T2DM.

Novel therapeutic diabetes approaches: The cardiovascular benefits beyond glucose control

10' education - Dec. 6, 2018 - WCC Dubai, UAE - Lina Badimon, MD Barcelona, Spain
Prof. Lina Badimon discusses several lines of evidence on the beneficial effects of novel antidiabetic therapeutic strategies that affect multiple body systems in addition to glucose metabolism.

Prof. Lina Badimon discusses several lines of evidence on the beneficial effects of novel antidiabetic therapeutic strategies that affect multiple body systems in addition to glucose metabolism.

Translating mechanisms of GLP-1RAs and SGLT2 inhibitors to CV benefits

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dr. Adie Viljoen, MD
Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits.

Cardio Diabetes Masterclass Dubai Dr. Viljoen discusses findings of the Harmony Outcomes and DECLARE trials, emphasizing how different mechanisms of GLP-1RAs and SGLT2 inhibitors translate into CV benefits .

Benefits of GLP-1RA and SGLT2-i in primary and secondary prevention of CVD in T2DM

Cardio Diabetes Masterclass, Dubai, United Arab Emirates

3' education - Jan. 28, 2019 - Dubai, United Arab Emirates - Prof. Eduard Montanya, MD
Prof. Montanya DMdiscusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trials, respectively.

Cardio Diabetes Masterclass Dubai Prof. Montanya discusses the positive results observed with albiglutide and dapagliflozin in the Harmony Outcomes and DECLARE trial, respectively.

Slides: Diabetes & CVD: Time for a multifactorial approach

Presentation prof John E Deanfield

Slides (presentation) - Dec. 6, 2018 - Dubai, UAE - John E Deanfield, MD – London, United Kingdom
This lecture by prof. John E Deanfield was part of a CME-accredited symposium

Slides as educational service to PACE members and meeting participants

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Treatment benefit of GLP-1RA in elderly with T2DM may vary with age

Literature - Dec. 18, 2018 - Gilbert MP et al., - Ann Intern Med. 2018
A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.

A posthoc analysis of the LEADER trial showed that liraglutide showed more pronounced CV benefits in T2DM patients aged 75 years or older, than in those between 60 and 74 years of age.

GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD
GLP-1 RA & CVD